- Home
- JMM vs IMMX Comparison
JMM vs IMMX Comparison
Compare JMM & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- IMMX
- Stock Information
- Founded
- JMM 1988
- IMMX 2014
- Country
- JMM United States
- IMMX United States
- Employees
- JMM N/A
- IMMX N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- JMM Finance
- IMMX Health Care
- Exchange
- JMM Nasdaq
- IMMX Nasdaq
- Market Cap
- JMM 56.8M
- IMMX 61.1M
- IPO Year
- JMM N/A
- IMMX 2021
- Fundamental
- Price
- JMM $5.98
- IMMX $2.04
- Analyst Decision
- JMM
- IMMX Strong Buy
- Analyst Count
- JMM 0
- IMMX 1
- Target Price
- JMM N/A
- IMMX $7.00
- AVG Volume (30 Days)
- JMM 16.1K
- IMMX 135.6K
- Earning Date
- JMM 01-01-0001
- IMMX 11-12-2024
- Dividend Yield
- JMM 5.44%
- IMMX N/A
- EPS Growth
- JMM N/A
- IMMX N/A
- EPS
- JMM N/A
- IMMX N/A
- Revenue
- JMM N/A
- IMMX N/A
- Revenue This Year
- JMM N/A
- IMMX N/A
- Revenue Next Year
- JMM N/A
- IMMX $200.00
- P/E Ratio
- JMM N/A
- IMMX N/A
- Revenue Growth
- JMM N/A
- IMMX N/A
- 52 Week Low
- JMM $5.29
- IMMX $1.26
- 52 Week High
- JMM $6.10
- IMMX $5.73
- Technical
- Relative Strength Index (RSI)
- JMM 43.26
- IMMX 46.03
- Support Level
- JMM $5.97
- IMMX $2.15
- Resistance Level
- JMM $6.14
- IMMX $2.49
- Average True Range (ATR)
- JMM 0.08
- IMMX 0.19
- MACD
- JMM -0.00
- IMMX -0.04
- Stochastic Oscillator
- JMM 30.43
- IMMX 23.70
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.